

A/REISSUE

PTO/SB/50 (12/97) (modified)

Approved for use through 09/30/00. OMB 0651-0033

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → ☐

REISSUE PATENT APPLICATION TRANSMITTAL

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EH49365125US

Date of Deposit February 13, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.


Thomas D. Mays

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

Attorney Docket No.

312762001430

Total Pages

15

First Named Inventor

Ann Monosov et al.

Original Patent Number

5,569,812

Original Patent Issue Date
(Month/Day/Year)

October 29, 1996

Express Mail Label No.

EH49365125US

APPLICATION FOR REISSUE OF:

(check applicable box)



Utility Patent



Design Patent



Plant Patent

APPLICATION ELEMENTS

1. ☒ Fee Transmittal Form (PTO/SB/56)
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification and Claims (amended, if appropriate)
3. ☐ Drawing(s) (proposed amendments, if appropriate)
4. ☒ Reissue Oath / Declaration (original or copy)
(37 CFR 1.175) (PTO/SB/51 or 52)
5. Original U.S. Patent
☒ Offer to Surrender Original Patent (37 CFR 1.178)
(PTO/SB/53 or PTO/SB/54)
or
☐ Ribboned Original Patent Grant
☐ Affidavit / Declaration of Loss (PTO/SB/55)
6. Original U.S. Patent Currently assigned?
☒ Yes ☐ No
If Yes, Check applicable box(es)
☒ Written Consent of all Assignees (PTO/SB/53 or 54)
☐ 37 CFR 3.73(b) Statement ☒ Power of Attorney

ACCOMPANYING APPLICATION PARTS

7. ☒ Transfer drawings from Patent File
8. ☐ Assignment Priority Claim (35 USC 119)
(if applicable)
9. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
10. ☐ English Translation of Reissue Oath/Declaration
(if applicable)
11. ☐ Small Entity Statement(s) ☐ Statement filed in prior application
Status still proper and desired
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. * ☐ Other:

15. CORRESPONDENCE ADDRESS

Thomas D. Mays
Registration No. 34,524

Morrison & Foerster LLP
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20006-1888
Telephone: (202) 887-8761
Facsimile: (202) 887-0763

- ☒ If a paper is untimely filed in the above-referenced application by applicant or his/her representative, the Assistant Commissioner is hereby petitioned under 37 C.F.R. § 1.136(a) for the minimum extension of time required to make said paper timely. In the event a petition for extension of time is made under the provisions of this paragraph, the Assistant Commissioner is hereby requested to charge any fee required under 37 C.F.R. § 1.17(a)-(d) to **Deposit Account No. 03-1952**. However, the Assistant Commissioner is **NOT** authorized to charge the cost of the issue fee to the Deposit Account.

The filing fee has been calculated as follows:


FOR	CLAIMS ON FILE AFTER THIS AMENDMENT MINUS HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	29-20	9	x \$22.00	\$198.00
INDEPENDENT CLAIMS	9-3	6	x \$82.00	\$492.00
			BASIC FEE	\$790.00
			TOTAL OF ABOVE CALCULATIONS =	\$1480.00
Reduction by ½ for filing by small entity (Note 37 C.F.R. §§ 1.9, 1.27, 1.28). If applicable, verified statement must be attached.				\$
Request for Abstract of Title				25.00
			TOTAL =	\$1505.00

- ☒ A check in the amount of \$1505.00 is attached.
- ☐ Please charge \$ to **Deposit Account No. 03-1952** referencing docket no. 312762001530.

Applicant(s) hereby petition(s) for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees or to credit any overpayment to **Deposit Account No. 03-1952** referencing docket no. 312762001530. A duplicate copy of this transmittal is enclosed, for that purpose.

Dated: February 13, 1998

Respectfully submitted,

By: 
Thomas D. Mays

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EH49365125US

Date of Deposit: February 13, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.



Thomas D. Mays

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the reissue application of:

Ann MONOSOV et al.

Patent No.: 5,569,812

Issue Date: October 29, 1996

For: NUDE MOUSE MODEL FOR HUMAN
NEOPLASTIC DISEASE

**REISSUE APPLICATION BY THE INVENTOR,
OFFER TO SURRENDER PURSUANT TO 37 C.F.R. § 1.178**

Box 7
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The undersigned applicant of the accompanying reissue application for the reissue of letters patent number 5,569,812, granted to him/her on October 29, 1996, for NUDE MOUSE MODEL FOR HUMAN NEOPLASTIC DISEASE, of which:

- ☐ he/she is now sole owner,
- ☒ is now sole owner by assignment, and on whose behalf and with whose assent the accompanying application is made,

hereby offers to surrender said letters patent.

Filed herewith is an:

☐ abstract of title, duly certified


☒ order for a title report

as required in such applications.

Dated: February 13, 1998

Respectfully submitted,

By:



Thomas D. Mays

Registration No. 34,524

2000 Pennsylvania Avenue, N.W.

Washington, D.C. 20006-1888

Telephone: (202) 887-8761

Facsimile: (202) 887-0763

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EH49365125US

Date of Deposit: February 13, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231


Thomas D. Mays

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the reissue application of:

Ann MONOSOV et al.

Patent No.: 5,569,812

Issue Date: October 29, 1996

For: NUDE MOUSE MODEL FOR HUMAN
NEOPLASTIC DISEASE

REISSUE APPLICATION BY ASSIGNEE,
OFFER TO SURRENDER PURSUANT TO 37 C.F.R. § 1.178

Box 7
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The undersigned applicant of the accompanying reissue application for the reissue of letters patent number 5,569,812, for NUDE MOUSE MODEL FOR HUMAN NEOPLASTIC DISEASE, granted on October 29, 1996, to Anticancer Incorporated, he is now owner by assignment of the entire interest, hereby offers to surrender said letters patent.


Filed herewith is an:

- ☐ abstract of title, duly certified,
- ☒ order for a title report

as required in such applications.

Dated: February 13, 1998

Respectfully submitted,

By: 

Thomas D. Mays

Registration No. 34,524

2000 Pennsylvania Avenue, N.W.

Washington, D.C. 20006-1888

Telephone: (202) 887-8761

Facsimile: (202) 887-0763



United States Patent [19]
Monosov et al.

[11] **Patent Number:** 5,569,812
[45] **Date of Patent:** * Oct. 29, 1996

[54] NUDE MOUSE MODEL FOR HUMAN NEOPLASTIC DISEASE

[75] **Inventors: Ann Monosov; Xinyu Fu, both of San Diego, Calif.**

[73] Assignee: Anticancer Incorporated, San Diego, Calif.

[*] Notice: The term of this patent shall not extend beyond the expiration date of Pat. No. 5,491,284.

[21] Appl. No.: 459,730

[22] Filed: Jun. 2, 1995

Related U.S. Application Data

[63] Continuation of Ser. No. 169,735, Dec. 17, 1993, Pat. No. 5,491,284, which is a continuation of Ser. No. 719,814, Jun. 24, 1991, abandoned, which is a continuation-in-part of Ser. No. 253,990, Oct. 5, 1988, abandoned.

[51] Int. Cl.^o A61K 35/00; A61K 49/00
[52] U.S. Cl. 800/2; 800/DIG. 5; 424/573;
424/559; 424/574; 424/557; 424/9.2
[58] Field of Search 800/2, DIG. 5;
424/573, 574, 559, 551, 556, 557, 9.2

[56] References Cited.

U.S. PATENT DOCUMENTS

5,491,284 2/1996 Monosov et al. 800/2

Primary Examiner—Jasemine C. Chambers
Attorney, Agent, or Firm—Baker, Maxham, Jester & Meadows

[57] **ABSTRACT**

A nude mouse model for human neoplastic disease having histologically intact human neoplastic tissue transplanted onto an organ of the mouse which corresponds to the human organ from which the tissue is obtained.

12 Claims, No Drawings

NUDE MOUSE MODEL FOR HUMAN NEOPLASTIC DISEASE

RELATED APPLICATIONS

5

This application is a continuation of U.S. Ser. No. 08/169,735, filed Dec. 17, 1993, now U.S. Pat. No. 5,491,284, which is a continuation of U.S. Ser. No. 07/719,814 filed Jun. 24, 1991, now abandoned, which is a continuation-in-part of U.S. Ser. No. 253,990 filed Oct. 5, 1988, now 10 abandoned, the contents of which are hereby incorporated by reference in their entirety.

TECHNICAL FIELD

15

The present invention relates generally to a non-human mammalian model for human neoplastic disease. More particularly, the invention relates to a non-human mammalian model having neoplastic tissue, obtained from a human organ, transplanted to the corresponding organ of the model. 20

BACKGROUND

There has long been a need for a representative animal model for human neoplastic disease. Such a model could serve many purposes. For example, it could be used to study the progression of neoplastic disease in human subjects and assist in finding appropriate treatment. Such a model could also be used to test the efficacy of proposed anti-neoplastic agents. Additionally, an animal model could be employed in individualized chemosensitivity testing of a cancer patient's tumors. The existence of such a model would make drug screening, testing and evaluation much more efficient and much less costly. 25

Some previous attempts at generating animal models for human neoplastic disease employed transplantable animal tumors. These were tumors that had developed in rodents and had been transplanted from animal to animal, usually in inbred populations. Other animal tumor models were generated by inducing tumors in the animals by means of various agents that were carcinogenic, at least in the animal system. Still other animal tumor models were rodents containing spontaneously-occurring tumors. These rodent models, however, frequently responded to chemotherapeutic agents very differently than human subjects receiving the same agent. 30

Another animal tumor model that developed starting some twenty years ago utilized mice without a thymus gland. These animals were deficient in cellular immunity and had therefore lost their ability to reject foreign transplant tissue. The mice, for reasons not clearly understood, were essentially lacking in hair and came to be called "nude mice" or "athymic T-cell deficient nude mice." 35

It was found that human tumors often grew when implanted subcutaneously under the skin of nude mice, however, the take rate or frequency with which human tumor tissue actually formed a tumor in the mouse varied depending on the individual donor and the tumor type. In these models, tumors that took exhibited histologically limited invasiveness and rarely metastasized, even if the original human tumor had been highly metastatic. Accordingly, the subcutaneous nude mouse human tumor model, although better than the previously described rodent model, still had substantial drawbacks, i.e. the subcutaneous transplants lacked the ability to metastasize, and also were often more sensitive than the tumor in the patient in the original organ. 40

The differences may be due to the subcutaneous environment regarding pH, vascularity, accessibility to drugs, etc.

Subsequent investigators found that invasion and metastases by human tumor cells in nude mice appeared to require that the cells be implanted orthotopically, i.e. injected into organs involved in the original anatomical environment of the tumor. For example, Wang et al. (Exp. Cell Biology, 50, 330 (1982)) report the expression of malignant phenotype when human colonic tumor cells were implanted by injection within the colonic wall of nude mice. Moreover, Naito et al. (Cancer Research, 46, 4109 (1986)) and Naito et al. (JNCI, 78,377 (1987)) report growth and metastasis of tumor cells isolated from a human renal cell carcinoma and implanted by injection into the kidneys of nude mice. More recently, Morikawa et al. (Cancer Research, 46, 6863 (1988)) report the growth of human colon carcinoma cells implanted by injection within the spleens of nude mice.

While the human tumor model created by orthotopic implantation of human tumor cells in the nude mouse represents a significant advance over earlier models, the value of this model is clearly dependent on the extent to which the character of the original human tumor is maintained in the immunodeficient host. Human tumor cells utilized in orthotopic implantation are derived from tumor tissue that is disassociated enzymatically. Enzymatic disassociation disrupts the architecture of the tumor tissue and thus the unique cellular organization. Cells behave very differently when they are organized in a tissue structure as opposed to being disassociated.

Neoplasms are biologically heterogeneous, consisting of different subpopulations of cells having different biological behavior and different metastatic potential (see Naito et al., Cancer Research, 46, 4109-4115 (1986); Naito et al., JNCI, 78,377 (1987); and Morikawa et al., Cancer Research, 48, 6863 (1988)). Enzymatic disassociation of tumor tissue, the conventional method used to isolate tumor cells from fresh surgical specimens, disrupts the original tumor architecture and precludes obtaining a truly representative tumor cell population for implantation. Enzymatic disassociation also alters cellular behavior and drug response.

For example, in routine isolation of tumor cells for implantation or sensitivity testing, tumor tissue from a surgical specimen is disassociated enzymatically to produce cells which are then implanted subcutaneously (s.c.) in nude mice. The purpose of the s.c. implant is to produce a larger amount of tumor tissue for studies of predictive sensitivity for therapeutic agents as well as for implantation. After sufficient s.c. tumor growth occurs, the tumor is excised and disassociated enzymatically. As mentioned previously, enzymatic disassociation of the tumor cells disrupts the tumor architecture and consequently cells that are selected for sensitivity testing or orthotopic implantation by injection may not be representative or characteristic of the original patient tumor.

Thus the art is presently lacking a truly adequate non-human mammalian model for human neoplastic disease. In particular, what is needed in the art is a model which has the ability to accurately mimic the progression of neoplastic disease as it occurs in a human subject. Such models and methods of generating same are disclosed and claimed herein.

SUMMARY AND OBJECTS OF THE INVENTION

The present invention relates to an improved non-human mammalian model for human neoplastic disease.

In yet a further aspect, the invention provides a method of generating a non-human mammalian model for human neoplastic disease, the method comprising, providing a non-human mammalian laboratory animal having sufficient immunodeficiency to allow implanted human neoplastic tissue to grow and mimic the progression of neoplastic disease in the human donor; and securing at least two pieces of neoplastic tissue from a human organ to the surface of the corresponding organ of the model.

Copending parent application, U.S. Ser. No. 253,990 filed Oct. 5, 1988, discloses animal models for human neoplastic

disease wherein human neoplastic tissue is implanted into the corresponding organ of an immunodeficient animal that has sufficient immunodeficiency to allow the transplanted neoplastic tissue to grow and mimic the progression of neoplastic disease in the human donor. The method used to generate the animal models disclosed in U.S. Ser. No. 253,990 is described in the following paragraphs and in Examples I, II and III.

Animals that are suitable as immunodeficient hosts include athymic rodents, i.e. rats and mice having no T-cell immunity. Particularly preferred animals are athymic mice which are readily available and may be obtained commercially from Charles River Laboratories, Inc., Wilmington, Mass. (Catalog identification: Crl:nu/nu(CD-1)BR, homozygous 28-42 days old).

The placement of neoplastic tissue in the immunodeficient host animal according to copending parent application, U.S. Ser. No. 253,990, is carried out by means of orthotopic implantation. This refers to an implant or graft transferred to a position formerly occupied by tissue of the same kind. The terminology orthotopic implantation is used to refer to the grafting of histologically intact human neoplastic tumor tissue from a human organ into the corresponding organ of an immunodeficient animal. Human neoplastic tissue that is utilized comprises tissue from fresh surgical specimens which are pathologically diagnosed tumors occurring in, for example, human kidney, liver, stomach, pancreas, colon, breast, prostate, lung, testis and brain. Such tumors include carcinomas as well as sarcomas and implantation thereof encompasses all stages, grades and types of tumors.

Prior to implantation, the human neoplastic tissue is maintained by placing it in a suitable nutrient medium, such as Eagle's Minimum Essential Medium containing ten percent fetal calf serum and a suitable antibiotic, such as gentamycin. The medium containing the tissue is then cooled to approximately 4° C. Tissue can be maintained in this manner for approximately twenty-four to seventy-two hours.

A selected tissue specimen is prepared for implantation by forming into a mass a suitable size for insertion into a suitably prepared cavity in the selected organ. The specimen size may vary from about 0.1×0.1×0.1 cm to about 0.2×0.1×0.1 cm. The technique used to form a specimen of suitable size comprises teasing the tissue to size by pulling into pieces of the desired size with forceps or the like.

Microsurgical instruments typically used to carry out tissue implantation include a castroviejo needle holder, jeweler's forceps (straight and curved), iris forceps, iris scissors and straight and curved tissue forceps, including one each with teeth and one each without teeth.

Prior to implantation of neoplastic tissue, the selected immunodeficient animal is anesthetized with a suitable anesthetic. Implantation of all organ tissue, except lung tissue, is conveniently accomplished by conventional anesthesia using ethyl ether. When lung tissue is implanted, pentobarbital is used as the anesthetic.

Implantation of tissue from a hepatoma or tumor from a human liver is carried out utilizing the caudal lobe of the recipient animal's liver as the implantation site. Several loose sutures are placed over the lobe and an incision is made longitudinally under the liver serosa to accommodate a tumor mass of approximately 0.1×0.1 cm in size. After placement of the tumor mass in the incision, the sutures are pulled snugly over the tumor in order to secure it in place.

The process of implantation of tissue from a human pancreatic tumor is carried out by making an incision in the

recipient animal's pancreas at the head of the organ near the duodenum. Care is exercised to select an avascular area. An incision is made in the selected area and a tumor mass of approximately $0.1 \times 0.1 \times 0.1$ cm is implanted in a manner identical to that described in the preceding paragraph. Tissue from all stages and all grades of pancreatic carcinoma may be implanted in this manner.

The implantation of tissue from a human mammary carcinoma is carried out by surgically implanting the tumor in the mammary fat pad of a recipient female animal. The tumor mass is approximately $0.1 \times 0.1 \times 0.1$ cm in size. After placement of the tumor in the pocket, the pocket is closed with a suture. All stages and grades of mammary carcinoma may be implanted in this manner.

Implantation of tissue from a human prostatic carcinoma into the prostate of a recipient animal is carried out by surgically forming an opening in the prostate and then placing 5 tissue specimens of approximately $0.1 \times 0.1 \times 0.1$ cm in size under the prostate capsule. After placement of the tissue specimen, the opening in the capsule is closed with appropriate sutures.

Implantation of tissue from a human testicular carcinoma into the testis of a recipient animal is carried out by penetrating the testis along the longitudinal axis with a number-18 gauge needle and injecting a tumor mass of approximately $0.1 \times 0.1 \times 0.1$ cm in size through the needle. When the end of the tumor specimen is visible at the tip of the needle, the needle is gently withdrawn while visible tumor tissue is held in place with forceps. The hole made by the needle is then closed with a single suture.

In preparation for implantation of neoplastic lung tissue into the lungs of the recipient animal, a tracheotomy is performed and plastic tubing is intubated. Thereafter, implantation may be effected by several procedures. In one implantation procedure, tracheotomy tubing is advanced to reach either lung lobe(s); a small ($0.1 \times 0.1 \times 0.1$ cm) tumor mass is injected through the tubing; and the tubing is then removed and the tracheal wound is closed with a suture.

In the other implantation procedure, precautionary tubing is inserted into the trachea; a small stab wound is made on the right chest to bring up a lobe of the right lung which plugs the thoracic cavity thereby preventing collapse of the lung; the lung lobe is gently clamped at the base and two ligatures are loosely placed on the lung; an incision is made on the lung, a tumor mass of approximately $0.1 \times 0.1 \times 0.1$ cm is imbedded therein; the ligatures are snugly tied; and the lung lobe is placed back into the thoracic cavity and the wound is closed. Tissue from all stages and grades of small cell and non-small cell lung carcinomas may be implanted by either of the foregoing procedures.

In order to implant neoplastic human brain tissue into the recipient animal's brain, a bur hole is made through the parietal cranial bone of the animal. A tumor mass of approximately $0.1 \times 0.1 \times 0.1$ cm is selected and implanted in the brain. The hole in the cranial bone is then sealed by means of bone wax.

The present invention is an extension and improvement of the invention disclosed in copending parent application U.S. Ser. No. 253,990 filed Oct. 5, 1988. In the present invention, a non-human mammalian model for human neoplastic disease is generated by improved methods of transplanting histologically intact neoplastic tissue from a human organ to the corresponding organ of an immunodeficient model that has sufficient immunodeficiency to allow the transplanted tissue to grow and mimic the progression of neoplastic disease in the human donor. The methods used to generate

the animal models of the present invention are described in the following paragraphs and in Examples IV-VII.

Transplantation of neoplastic tissue from a human organ to the corresponding organ of an immunodeficient animal as taught in the present invention is referred to as orthotopic transplantation. In the present invention, the terminology orthotopic transplantation is used to refer to the grafting of histologically intact human neoplastic tumor tissue from a human organ onto the corresponding organ of an immunodeficient animal.

Human neoplastic tissue that can be utilized in the present invention as well as preparation of such tissue has been described earlier in connection with copending parent application U.S. Ser. No. 253,990.

One preferred method for transplanting human neoplastic tissue to an immunodeficient animal model according to the present invention utilizes a vascularizing matrix. The purpose of the matrix is to induce the development of blood vessels and thereby enhance the survival and growth of the transplanted neoplastic tissue. In this method, the matrix is transplanted on the appropriate organ by means of a surgical suture(s). When the matrix becomes well vascularized, which usually occurs in about twenty (20) days, the histologically intact specimen of human neoplastic tissue is implanted directly into the vascularized matrix. The term vascularizing matrix as used herein refers to liquid-permeable, water-insoluble material having the general physical characteristics of a sponge and being substantially absorbable in a living mammalian body. Specific examples of such materials are absorbable gelatin sponge and cellulose sponge. While absorbable gelatin sponge is the preferred vascularizing matrix, those skilled in the art will realize that a number of materials can be utilized as the vascularizing matrix.

Another preferred method of transplanting human neoplastic tissue according to the present invention utilizes an internal skin flap over the transplanted surgical specimen. Use of the skin flap induces vascularization and take of the transplanted tissue. In this method, a U shaped incision is made in the abdomen of the immunodeficient animal model and the resulting skin flap is lifted up and the abdominal wall is opened along the linea alba. The cecum (or other organ) is accessed through the abdominal incision, and neoplastic tissue is placed between the cecum serosa (or other organ) and the skin flap. Surgical sutures are applied along the edge of the skin flap to fix the flap to the cecum (or other organ). The cecum (or other organ) together with the skin flap is put back into the abdominal cavity and peritoneum and rectus muscles are closed with sutures. Finally, the skin layer is also closed with sutures and surgical adhesive is applied to ensure a good closure of the abdominal wall.


Still another preferred method of transplanting human neoplastic tissue to an immunodeficient animal model according to the present invention utilizes multiple pieces of tissue arranged in a shish-kabob configuration. In this method, a thread-like material is passed through at least two pieces of human neoplastic tissue and the resulting tissue arrangement is positioned on the surface of the corresponding organ of the immunodeficient model. The shish-kabob configuration is attached to the animal organ by securing a pair of terminal ends of the thread-like material to the organ. The term thread-like material as used herein refers to absorbable surgical suture such as, for example, Chromic Gut surgical suture and Coated VicrylR surgical suture, both obtainable from Ethicon, Inc. located in Somerville, N.J. A particularly preferred variation of this method of transplan-

Variable	Mean	SD	Min	Max
Age	30.5	5.2	18	45
Gender	0.5	0.5	0	1
Marital status	0.3	0.5	0	1
Education	12.5	1.5	9	16
Income	1500	500	500	3000
Health status	0.7	0.4	0	1
Smoking status	0.2	0.4	0	1
Alcohol consumption	0.1	0.3	0	1
Exercise frequency	0.5	0.5	0	1
Stress level	0.6	0.4	0	1
Sleep quality	0.8	0.3	0	1
Work satisfaction	0.7	0.4	0	1
Life satisfaction	0.9	0.2	0	1
Depression score	0.3	0.4	0	1
Anxiety score	0.2	0.3	0	1
Resilience score	0.6	0.4	0	1
Optimism score	0.7	0.4	0	1
Gratitude score	0.8	0.3	0	1
Forgiveness score	0.9	0.2	0	1
Self-compassion score	0.7	0.4	0	1
Emotional regulation score	0.8	0.3	0	1
Prosocial behavior score	0.6	0.4	0	1
Life purpose score	0.7	0.4	0	1
Meaning in life score	0.8	0.3	0	1
Existential well-being score	0.9	0.2	0	1
Overall well-being score	0.8	0.3	0	1

Variable	Mean	SD	Min	Max
Age	30.5	5.2	18	45
Gender	0.5	0.5	0	1
Marital status	0.3	0.5	0	1
Education	12.5	1.5	9	16
Income	1500	500	500	3000
Health status	0.7	0.4	0	1
Smoking status	0.2	0.4	0	1
Alcohol consumption	0.1	0.3	0	1
Exercise frequency	0.5	0.5	0	1
Stress level	0.6	0.4	0	1
Sleep quality	0.8	0.3	0	1
Work satisfaction	0.7	0.4	0	1
Life satisfaction	0.9	0.2	0	1
Depression score	0.3	0.4	0	1
Anxiety score	0.2	0.3	0	1
Resilience score	0.6	0.4	0	1
Optimism score	0.7	0.4	0	1
Gratitude score	0.8	0.3	0	1
Forgiveness score	0.9	0.2	0	1
Self-compassion score	0.7	0.4	0	1
Emotional regulation score	0.8	0.3	0	1
Prosocial behavior score	0.6	0.4	0	1
Life purpose score	0.7	0.4	0	1
Meaning in life score	0.8	0.3	0	1
Existential well-being score	0.9	0.2	0	1
Overall well-being score	0.8	0.3	0	1

Variable	Mean	SD	Min	Max
Age	30.5	5.2	18	45
Gender	0.5	0.5	0	1
Marital status	0.3	0.5	0	1
Education	12.5	1.5	9	16
Income	1500	500	500	3000
Health status	0.7	0.4	0	1
Smoking status	0.2	0.4	0	1
Alcohol consumption	0.1	0.3	0	1
Exercise frequency	0.5	0.5	0	1
Stress level	0.6	0.4	0	1
Sleep quality	0.8	0.3	0	1
Work satisfaction	0.7	0.4	0	1
Life satisfaction	0.9	0.2	0	1
Depression score	0.3	0.4	0	1
Anxiety score	0.2	0.3	0	1
Resilience score	0.6	0.4	0	1
Optimism score	0.7	0.4	0	1
Gratitude score	0.8	0.3	0	1
Forgiveness score	0.9	0.2	0	1
Self-compassion score	0.7	0.4	0	1
Emotional regulation score	0.8	0.3	0	1
Prosocial behavior score	0.6	0.4	0	1
Life purpose score	0.7	0.4	0	1
Meaning in life score	0.8	0.3	0	1
Existential well-being score	0.9	0.2	0	1
Overall well-being score	0.8	0.3	0	1

[illegible][illegible][illegible][illegible][illegible][illegible][illegible]



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the reissue application of:

Ann MONOSOV et al.

Patent No.: 5,569,812

Issue Date: October 29, 1996

For: NUDE MOUSE MODEL FOR HUMAN
NEOPLASTIC DISEASE

**REISSUE APPLICATION DECLARATION AND POWER OF ATTORNEY
BY INVENTOR**

Box 7
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, I believe I am first and joint inventor of the subject matter that is described and claimed in letters patent number 5,569,812, granted on October 29, 1996, and in the foregoing specification, and for which invention I solicit a reissue patent.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 C.F.R. § 1.56(a) and (b).

☐ In compliance with this duty, there is attached an information disclosure statement in accordance with 37 C.F.R. § 1.98

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

EARLIEST FOREIGN APPLICATION(S) IF ANY FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
COUNTRY (if PCT indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. § 119
*			<input type="checkbox"/> YES <input type="checkbox"/> NO

ALL FOREIGN APPLICATION(S) IF ANY FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
COUNTRY (if PCT indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. § 119
*			<input type="checkbox"/> YES <input type="checkbox"/> NO

STATEMENT OF INOPERATIVENESS OR INVALIDITY OR INVALIDITY OF ORIGINAL PATENT

That I believe the original patent to be

- ☒ partly
☐ wholly

inoperative or invalid **because of error without any deceptive intent on the part of the applicant** pursuant to 37 C.F.R. § 1.175(a)(6).

The statement below specifies the errors relied upon, and how they arose pursuant to 37 C.F.R. § 1.175(a)(5).

- ☐ why the original patent is believed to be wholly or partly inoperative or invalid (37 C.F.R. § 1.175(a)(1);
- ☐ particularly the defects upon which the claim that such patent is inoperative or invalid "by reason of a defective specification or drawing" is based (37 C.F.R. § 1.175(a)(3); and or

- ☒ distinctly the excess or insufficiency in the claims that make the patent inoperative or invalid "by reason of the patentee claiming more or less than he had a right to claim in the patent." (37 C.F.R. § 1.175(a)(3);
- ☐ Corroborating affidavits or declarations of others accompany this declaration. (37 C.F.R. § 1.175(b).

STATEMENT OF INOPERATIVENESS OR INVALIDITY OF ORIGINAL PATENT

Applicants present this Declaration in support of the above-captioned application for reissue of U.S. Patent No. 5,569,812 to correct certain errors in the prosecution of the original patent which are discussed in this Declaration.

1. U.S. Patent No. 5,569,812 ("812 patent") issued on October 29, 1996, from Application No. 459,730, filed on June 2, 1995; which is a continuation of Application No. 169,735, filed on December 17, 1993, which issued on February 13, 1996 as U.S. Patent 5,491,284, which is a continuation of Application No. 719,814, filed on June 24, 1991, now abandoned; which is a continuation-in-part of Application No. 253,990, filed October 5, 1988, now abandoned.

2. The present claims of the '812 patent are drawn to a nude mouse model for human neoplastic disease and to a method of generating a nude mouse model for human neoplastic disease. The composition and method of generating relate to a nude mouse having histologically intact human neoplastic tissue of at least 1 mm³ in size transplanted onto an organ of said mouse which corresponds to the human organ from which said tissue is originally obtained; and having sufficient immuno-deficiency to allow said transplanted neoplastic tissue to grow and mimic the progression of the neoplastic disease in the human donor.

3. The attorney of record who filed and prosecuted the applications which subsequently issued as the '812 patent committed an error on his part, apparently without any deceptive intent, by failing to recognize the full breadth and pioneering nature of the present invention and by accepting claims of a narrower scope than that to which Applicant was entitled. These unduly narrowed claims have resulted in the partial inoperativeness or invalidity of the '812 patent by

reason of the patentee claiming less that he had a right to claim in the patent. (37 C.F.R. § 1.175(a)(3))

4. These errors in claims 1-12 may be deemed to render the claims as granted wholly or partly invalid and therefore should be corrected.

5. The original claims 1-12 are filed herewith without any modifications or amendments thereto. Also presented are new claims 13-29, which seek to broaden the scope of claims as originally issued. Applicant hereby reserves the right to subsequently amend the claims for the purpose of seeking additional breadth in claim scope as appropriate and necessary.

6. Claims 13, 14, 20, and 21 are drawn to compositions and methods of generating a nude rodent model and specifically in claims 14 and 21, wherein said rodent is a rat. The original specification provides basis for these claims at column 4, lines 9-11, and in view of the disclosure at column 2, line 66 to column 3, line 62.

7. Claims 15-17 and 22-24 are drawn to compositions and methods of generating an immunodeficient rodent model and specifically in claims 16 and 23, wherein said rodent is a rat and specifically in claims 17 and 24, wherein said rodent is a mouse. The original specification provides basis for these claims at column 4, lines 9-11, and in view of the disclosure at column 2, line 66 to column 3, line 62.

8. Claims 18 and 25 are drawn to compositions and methods of generating an immunodeficient rodent model and specifically wherein said rodent is a severe combined immunodeficient (SCID) mouse. The original specification provides basis for these claims at column 4, lines 9-11, and in view of the disclosure at column 2, line 66 to column 3, line 62 and in view of the art at the time of the original filing of the '990 application which recognized that SCID mice were immunodeficient due to a lack of mature T-cells.

9. Claims 19 and 26 are drawn to compositions and methods of generating an immunodeficient non-human mammal model. The original specification provides basis for these claims at column 4, lines 9-11, and in view of the disclosure at column 2, line 66 to column 3, line 62.

20. Claims 27-29 are drawn to compositions of immunodeficient models, wherein is deleted the size limitation of 1 mm³ relating to the histologically intact human neoplastic tissue that is transplanted onto an organ of said immunodeficient models. This size limitation was included at the close of prosecution in the '730 application, apparently in response to a rejection of the claims under 35 U.S.C. § 112, second paragraph.

POWER OF ATTORNEY

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith

Thomas E. Ciotti (Reg No. 21,013)
Gladys H. Monroy (Reg No. 32,430)
Paul Schenck (Reg No. 27,253)
Freddie K. Park (Reg No. 35,636)
Shmuel Livnat (Reg No. 33,949)
Antoinette F. Konski (Reg No. 34,202)
Stuart P. Kaler (Reg No. 35,913)
Robert Saltzberg (Reg No. 36,910)
Mani Adeli (Reg No. 39,585)
Sean Brennan (Reg No. 39,917)
Robert K. Cerpa (Reg No. 39,933)
Lee K. Tan (Reg No. 39,447)
Madeline I. Johnston (Reg No. 36,174)
Stephen C. Durant (Reg No. 31,506)
Hector Gallegos (Reg No. 40,614)
Charles D. Holland (Reg No. 35,196)
Michael Hetherington (Reg No. 32,357)
Thomas D. Mays (Reg No. 34,524)
Wen Liu (Reg No. 32,822)
Cindy S. Kaplan (Reg No. 40,043)

Kate H. Murashige (Reg No. 29,959)
Debra A. Shetka (Reg No. 33,309)
E. Thomas Wheelock (Reg No. 28,825)
Susan K. Lehnhardt (Reg No. 33,943)
Tyler Dylan (Reg No. 37,612)
Harry J. Macey (Reg No. 32,818)
David L. Bradfute (Reg No. 39,117)
Laurie A. Axford (Reg No. 35,053)
Catherine M. Polizzi (Reg No. 40,130)
J. Michael Schiff (Reg No. 40,253)
Ronald D. Devore (Reg No. 39,958)
Alan W. Cannon (Reg No. 34,977)
Dahna S. Pasternak (Reg No. 41,411)
Frank Wu (Reg No. 41,386)
Barry E. Bretschneider (Reg No. 28,055)
Mark R. Carter (Reg No. 39,131)
Edward V. Donahue (Reg No. 35,492)
Thomas G. Wiseman (Reg No. 35,046)
Ararat Kapouytian (Reg No. 40,044)

- ☐ . Attached as part of this declaration and power of attorney is the authorization of the above-named attorney(s) to accept and follow instructions from my representative.

all of Morrison & Foerster LLP, 2000 Pennsylvania Avenue, N.W., Washington, D.C. 20006-1888, telephone (202) 887-1500, to prosecute this application and transact all matters in the United States Patent and Trademark Office connected therewith.

Please direct all written communications relative to this application to:

Thomas D. Mays
Morrison & Foerster LLP
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20006-1888

Please direct all telephone communications to Thomas D. Mays at (202) 887-8761.


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date

Name: Ann Monosov
Residence: San Diego, CA
Citizenship: Russia
Post Office Address: 8148 Genesee Ave., Suite 120
San Diego, CA 92122

5/1/98

Date


Name: Xinyu Fu
Residence: Providence, RI
Citizenship: China
Post Office Address: Rhode Island Hospital, Brown University
Providence, RI

comparing the samples with a tissue sample from the tissue donor.

Preparation of the tissue samples for histological analysis was carried out by (1) fixing the sample in formalin; (2) embedding the fixed sample in paraffin; (3) preparing 5-mi-
5 cron sections of the fixed, embedded sample; (4) staining the sections with hematoxylin and eosin; and (5) microscopically observing the tissue structure in each section.

Histological analysis revealed that the tissue in the recipi-
0 ent animals preserved its architecture and tissue type and mimicked progression of the disease in the human donor.

EXAMPLE II

5 In this example, specimens of human tissue excised from the stomach and pathologically diagnosed as gastric carcinoma were prepared to size by the teasing procedure described earlier.

20 Five athymic nude mice age four (4) to six (6) weeks were selected as the animal recipients for the implants. In preparation for surgery, the mice were anesthetized with ether.

Each anesthetized mouse was opened to provide access to the stomach. An incision was made in the stomach wall using a number 11 scalpel taking care not to penetrate the
25 mucosal layer. A pocket was formed large enough to receive five tumor masses of about $0.1 \times 0.1 \times 0.1$ cm each. A tumor piece of approximately this size was selected and inserted into the pocket and the incision was closed using a 7-0 suture.

10 The five mice of this example have survived for about three (3) to four (4) months and otherwise appear healthy. Subsequent surgical opening of the stomach of these mice has verified that the tumors have taken.

EXAMPLE III

In this example, specimens of human tissue removed from a human colon and pathologically diagnosed as colon carcinoma were prepared to size by the teasing procedure
10 described earlier.

Five athymic nude mice, age four (4) to six (6) weeks were selected as the animal recipients for the implants. In preparation for surgery, the mice were anesthetized with
15 ether. Each anesthetized mouse was opened to provide access to the colon. A pocket or cavity was surgically formed in the seromuscular layer with care exercised not to enter the lumen. Five to ten tumor masses of approximately $0.1 \times 0.1 \times 0.1$ cm each were inserted into the pocket which was then closed with a suture.

Four of the five mice which underwent this implant surgery have survived for three to four months and appear to be in good health. Approximately one month following tissue implantation, the mice were surgically opened and the
20 tumors were observed to have taken.

EXAMPLE IV

This example relates to the use of a vascularizing matrix
50 to induce vascularization and take of orthotopically transplanted human tumor tissue.

A surgical tissue specimen, removed from a human colon and pathologically diagnosed as colon carcinoma, was washed with colon-wash medium. Necrotic tissue was
65 removed and the tumor was then cut into small pieces (about 1-mm^3). Colon-wash medium, used to remove infectious intestinal material, was formulated by combining 500 ml of

Minimum Essential Medium with Earle's salts (MEM Earle's) with 70 ml fetal bovine serum, 75.2 mg Penicillin G sodium salt, 125 mg Streptomycin, 10 ml Fungizone antibiotic (250 ug amphotericin B and 205 ug sodium deoxycholate/ml in deionized distilled water), 5 mg Tetracycline, 50 mg Amikacin, 75 mg chloramphenicol and 50 mg Gentamycin.

GelfoamR brand of absorbable, sterile gelatin sponge (obtained from The Upjohn Co., Kalamazoo, Mich.) was hydrated with MEM Earle's. The hydrated sponge was cut into approximately 0.3-0.5x0.3-0.5x0.3-0.5 cm pieces which were transplanted onto the cecum of nude mice by means of a simple surgical suture on top of the cecum serosa. After 20 days, the sponges became well vascularized.

The transplanted vascularized sponges were cut in the center to make a pocket and about 10-15 of the previously prepared 1-mm³ tumor pieces were implanted into each pocket which was closed by means of a surgical suture. The tumor grew locally and regional as well as liver metastases occurred.

EXAMPLE V

This example relates to the use of an internal skin flap to induce vascularization and take of orthotopically implanted human tumor tissue.

The tumor tissue used is identical to tissue used in Example IV and was prepared for implantation according to the procedure described in Example IV.

Skin flaps were constructed in the lower abdomen of nude mice by making incisions along three sides of a rectangular area (a U-shaped incision). The flap was lifted up and the abdominal wall was opened along the linea alba. The cecum was exteriorized from the abdominal cavity and tumor pieces (about 1-mm³) were placed between the cecum serosa and the skin flap. Surgical sutures were applied along the two opposing edges of the flap to fix the flap on the cecum. The cecum, together with the skin flap was put back into the abdominal cavity. Peritoneum and rectus muscles were closed with sutures followed by reattachment of the skin flap with sutures. As a last step, surgical adhesive was applied to ensure good closure of the abdominal wall. The tumor grew at the implanted site and formed abdominal metastases.

EXAMPLE VI

This example relates to the use of a shish-kabob tissue configuration to effect orthotopic transplantation of human tumor tissue.

A surgical tissue specimen, removed from a human colon and pathologically diagnosed as colon carcinoma, was well washed with colon-wash medium. Necrotic tissue was removed and the tumor was then cut into small 1-mm³ pieces. Eight of the 1-mm³ pieces were assembled in a shish-kabob configuration by stringing the pieces together on a piece of surgical suture.

The shish-kabob tissue configuration was transplanted in nude mice by placement of the configuration on the mouse colon approximately 0.5 to 1 cm away from (i.e., up-stream of) the animal's cecum. The configuration is held in place by securing the terminal ends of the suture material to the organ of the animal.

EXAMPLE VII

As shown below, local growth, regional metastasis, and in some instances, distant organ metastasis has been achieved using the three novel methods of orthotopic transplantation described in the present invention.

TABLE 1

Orthotopic Transplantation of Human Colon Carcinoma to the Colon of Nude Mice				
Method	Number of Animals	Local Growth	Regional Metastasis	Distant Metastasis
Matrix	3	56-62 days	56-62 days	160 days
Skin Flap	3	48-62 days	48-62 days	
Shish- kabob	4	62-138 days	62-138 days	

EXAMPLE VIII

This example relates to the use of surgical adhesive to glue a piece of tumor tissue onto the top of the urinary bladder of the nude mouse.

A piece of tumor tissue specimen about 2-mm³ size was prepared for tumor transplantation. The nude mouse was operated on under surgical anesthesia with the full exposure of the urinary bladder. A small amount of surgical adhesive (2-cyanoacrylic acid ester) was applied on the top of the urinary bladder and the previously prepared tumor piece was then glued onto the top of the urinary bladder. The abdomen was closed with surgical sutures.

Using the transplantation method described above, we transplanted the ras-transfected human bladder RT-10 carcinoma cell line xenograft. As a result, we achieved unexpected extensive growth and metastases, including invasion of the whole thickness of the urinary bladder wall, lymph node metastases, and multi-organ metastases in the liver, pancreas, spleen, ovary, kidney, ureter and lung. This transplantation result of RT-10 is in striking contrast to the result obtained when RT-10 was injected transurethrally as disaggregated cells where only local invasion and no distant metastasis were observed. (Theodorescu et al., Proc. Natl. Acad. Sci(1990), Vol 87, 9047-9051.)

EXAMPLE IX

In this example, a human tongue cancer specimen, which was prepared by being cut into 1-mm³ pieces, was transplanted orthotopically to the floor of the mouth of a nude mouse.

An incision was made along the midline on the upper neck of the mouse. After blunt dissection of the muscles of the floor of the mouth, five pieces of prepared tumor tissue were implanted in between the muscles deep in the floor of the mouth. Surgical sutures were applied to close the dissected muscles and skin layer.

Extremely invasive growth was observed which involved the whole jaw as well as deep in the nasopharynx. This is distinctly different from growth observed when tumor pieces were implanted subcutaneously in the neck area. The subcutaneously grown tumor was completely encapsulated and exhibited no invasion of the adjacent tissue.

EXAMPLE X

In this example, a human pancreatic tumor specimen was prepared by being cut into 1-mm³ pieces, and tumor pieces were transplanted onto the nude mouse pancreas.

A midline incision was made on the upper abdomen of the nude mouse muscle layers and the peritoneum were opened along the linea alba. Ten (10) pieces of previously prepared

[illegible][illegible][illegible][illegible]

- [illegible]

[illegible][illegible]

- [illegible]

[illegible][illegible]

5. A nude mouse model according to claim 2 wherein said neoplastic tissue is obtained from human ovarian tissue.

6. A nude mouse model according to claim 5 wherein said human neoplastic ovarian tissue is implanted in the ovarian capsule of the mouse.

7. A nude mouse model according to claim 5 wherein said human neoplastic ovarian tissue is transplanted by securing to the surface of the mouse ovary at least two pieces of neoplastic tissue in close proximity to each other.

8. A nude mouse model according to claim 2 wherein said neoplastic tissue is obtained from human pleural tissue.

9. A nude mouse model according to claim 8 wherein said neoplastic tissue is implanted in the parietal pleura of the mouse.

10. A nude mouse model according to claim 9 wherein said neoplastic tissue is implanted in the visceral pleura of the mouse.

11. A method of generating a nude mouse model for human neoplastic disease, said method comprising:

- transplanting histologically intact human neoplastic tissue of at least 1 mm³ in size onto an organ of a nude mouse which corresponds to the human organ from which said tissue is originally obtained; and
- allowing said transplanted tissue to grow and mimic progression of the neoplastic disease in the human donor.

12. A method of generating a nude mouse according to claim 11 wherein said human neoplastic tissue is selected from breast tissue, ovarian tissue or pleural tissue.

* * * * *

13. A nude rodent model for human neoplastic disease, wherein said rodent is characterized by:

having histologically intact human neoplastic tissue of at least 1 mm³ in size transplanted onto an organ of said rodent which corresponds to the human organ from which said tissue is originally obtained; and

having sufficient immuno-deficiency to allow said transplanted neoplastic tissue to grow and mimic the progression of the neoplastic disease in the human donor.

14. The nude rodent model for human neoplastic disease of claim 13, wherein said rodent is a rat.

15. An immunodeficient rodent model for human neoplastic disease, wherein said rodent is characterized by:

having histologically intact human neoplastic tissue of at least 1 mm³ in size transplanted onto an organ of said rodent which corresponds to the human organ from which said tissue is originally obtained; and

having sufficient immuno-deficiency to allow said transplanted neoplastic tissue to grow and mimic the progression of the neoplastic disease in the human donor.

16. The immunodeficient rodent model for human neoplastic disease of claim 15, wherein said rodent is a rat.

17. The immunodeficient rodent model for human neoplastic disease of claim 15, wherein said rodent is a mouse.

18. The immunodeficient rodent model for human neoplastic disease of claim 17, wherein said rodent is a severe combined immunodeficient (SCID) mouse.

19. An immunodeficient non-human mammal model for human neoplastic disease, wherein said non-human mammal model is characterized by:

having histologically intact human neoplastic tissue of at least 1 mm³ in size transplanted onto an organ of said non-human mammal which corresponds to the human organ from which said tissue is originally obtained; and

having sufficient immuno-deficiency to allow said transplanted neoplastic tissue to grow and mimic the progression of the neoplastic disease in the human donor.

20. A method of generating a nude rodent model for human neoplastic disease, said method comprising:

transplanting histologically intact human neoplastic tissue of at least 1 mm³ in size onto an organ of a nude rodent which corresponds to the human organ from which said tissue is originally obtained; and

allowing said transplanted tissue to grow and mimic progression of the neoplastic disease in the human donor.

21. The method of generating a nude rodent model for human neoplastic disease of claim 20, wherein said rodent is a rat.

22. A method of generating an immunodeficient rodent model for human neoplastic disease, said method comprising:

transplanting histologically intact human neoplastic tissue of at least 1 mm³ in size onto an organ of an immunodeficient rodent which corresponds to the human organ from which said tissue is originally obtained; and

allowing said transplanted tissue to grow and mimic progression of the neoplastic disease in the human donor.

- 5 -

23. The method of generating an immunodeficient rodent model for human neoplastic disease of claim 22, wherein said rodent is a rat.

24. The method of generating an immunodeficient rodent model for human neoplastic disease of claim 22, wherein said rodent is a mouse.

25. The method of generating an immunodeficient rodent model for human neoplastic disease of claim 24, wherein said rodent is a severe combined immunodeficient (SCID) mouse.

26. A method of generating an immunodeficient non-human mammal model for human neoplastic disease, said method comprising:
transplanting histologically intact human neoplastic tissue of at least 1 mm³ in size onto an organ of an immunodeficient non-human mammal which corresponds to the human organ from which said tissue is originally obtained; and
allowing said transplanted tissue to grow and mimic progression of the neoplastic disease in the human donor.

27. A nude rodent model for human neoplastic disease, wherein said rodent is characterized by:
having histologically intact human neoplastic tissue transplanted onto an organ of said rodent which corresponds to the human organ from which said tissue is originally obtained; and
having sufficient immuno-deficiency to allow said transplanted neoplastic tissue to grow and mimic the progression of the neoplastic disease in the human donor.

28. An immunodeficient rodent model for human neoplastic disease, wherein said rodent is characterized by:

- 6 -

having histologically intact human neoplastic tissue transplanted onto an organ of said rodent which corresponds to the human organ from which said tissue is originally obtained; and

having sufficient immuno-deficiency to allow said transplanted neoplastic tissue to grow and mimic the progression of the neoplastic disease in the human donor.

29. An immunodeficient non-human mammal model for human neoplastic disease, wherein said non-human mammal model is characterized by:

having histologically intact human neoplastic tissue transplanted onto an organ of said non-human mammal which corresponds to the human organ from which said tissue is originally obtained; and

having sufficient immuno-deficiency to allow said transplanted neoplastic tissue to grow and mimic the progression of the neoplastic disease in the human donor.

Van/TDM
9/22/98

#3
PATENT

Docket No. 312762001430

SEP 21 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In the reissue application of:

Ann MONOSOV et al.

Patent No.: 5,491,284

Issue Date: February 13, 1996

For: NUDE MOUSE MODEL FOR
NEOPLASTIC DISEASE



**REISSUE APPLICATION DECLARATION AND POWER OF ATTORNEY
BY INVENTOR**

Box 7
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, I believe I am first and joint inventor of the subject matter that is described and claimed in letters patent number 5,491,284, granted on February 13, 1996, and in the foregoing specification, and for which invention I solicit a reissue patent.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 C.F.R. § 1.56(a) and (b).

☐ In compliance with this duty, there is attached an information disclosure statement in accordance with 37 C.F.R. § 1.98

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

EARLIEST FOREIGN APPLICATION(S) IF ANY FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
COUNTRY (if PCT indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. § 119
*			<input type="checkbox"/> YES <input type="checkbox"/> NO

ALL FOREIGN APPLICATION(S) IF ANY FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
COUNTRY (if PCT indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. § 119
*			<input type="checkbox"/> YES <input type="checkbox"/> NO

STATEMENT OF INOPERATIVENESS OR INVALIDITY OR INVALIDITY OF ORIGINAL PATENT

That I believe the original patent to be

- ☒ partly
☐ wholly

inoperative or invalid **because of error without any deceptive intent on the part of the applicant** pursuant to 37 C.F.R. § 1.175(a)(6).

The statement below specifies the errors relied upon, and how they arose pursuant to 37 C.F.R. § 1.175(a)(5).

- ☐ why the original patent is believed to be wholly or partly inoperative or invalid (37 C.F.R. § 1.175(a)(1);
- ☐ particularly the defects upon which the claim that such patent is inoperative or invalid "by reason of a defective specification or drawing" is based (37 C.F.R. § 1.175(a)(3); and or

- ☒ distinctly the excess or insufficiency in the claims that make the patent inoperative or invalid "by reason of the patentee claiming more or less than he had a right to claim in the patent." (37 C.F.R. § 1.175(a)(3));
- ☐ Corroborating affidavits or declarations of others accompany this declaration. (37 C.F.R. § 1.175(b)).

STATEMENT OF INOPERATIVENESS OR INVALIDITY OF ORIGINAL PATENT

Applicants present this Declaration in support of the above-captioned application for reissue of U.S. Patent No. 5,491,284 to correct certain errors in the prosecution of the original patent which are discussed in this Declaration.

1. U.S. Patent No. 5,491,284 ("284 patent") issued on February 13, 1996, from Application No. 169,735, filed on December 17, 1993; which is a continuation of Application No. 719,814, filed on June 24, 1991, now abandoned; which is a continuation-in-part of Application No. 253,990, filed October 5, 1988, now abandoned.

2. The present claims of the '284 patent are drawn to a nude mouse model for human neoplastic disease and a method of generating a nude mouse model for human neoplastic disease. The composition and method of generating relate to a nude mouse having histologically intact human neoplastic tissue of at least 1mm³ in size transplanted onto an organ of said mouse which corresponds to the human organ from which said tissue is originally obtained; and having sufficient immuno-deficiency to allow said transplanted neoplastic tissue to grow and mimic the progression of the neoplastic disease in the human donor; wherein said human neoplastic tissue is selected from stomach, colon, pancreatic or lung tissue.

3. The attorney of record who filed and prosecuted the applications which subsequently issued as the '284 patent committed an error on his part, apparently without any deceptive intent, by failing to recognize the full breadth and pioneering nature of the present invention and by accepting claims of a narrower scope than that to which Applicant was entitled. These unduly narrowed claims have resulted in the partial inoperativeness or invalidity of the '284 patent by reason of the patentee claiming less than he had a right to claim in the patent. (37 C.F.R. § 1.175(a)(3))

4. These errors in claims 1-21 may be deemed to render the claims as granted wholly or partly invalid and therefore should be corrected.

5. The original claims 1-21 are filed herewith without any modifications or amendments thereto. Also presented are new claims 22-38, which seek to broaden the scope of claims as originally issued. Applicant hereby reserves the right to subsequently amend the claims for the purpose of seeking additional breadth in claim scope as appropriate and necessary.

6. Claims 22, 23, 29, and 30 are drawn to compositions and methods of generating a nude rodent model and specifically in claims 23 and 30, wherein said rodent is a rat. The original specification provides basis for these claims at column 4, lines 9-11, and in view of the disclosure at column 2, line 66 to column 3, line 62.

7. Claims 24-26 and 31-33 are drawn to compositions and methods of generating an immunodeficient rodent model and specifically in claims 25 and 30, wherein said rodent is a rat and specifically in claims 26 and 33, wherein said rodent is a mouse. The original specification provides basis for these claims at column 4, lines 9-11, and in view of the disclosure at column 2, line 66 to column 3, line 62.

8. Claims 27 and 34 are drawn to compositions and methods of generating an immunodeficient rodent model and specifically wherein said rodent is a severe combined immunodeficient (SCID) mouse. The original specification provides basis for these claims at column 4, lines 9-11, and in view of the disclosure at column 2, line 66 to column 3, line 62 and in view of the art at the time of the original filing of the '990 application which recognized that SCID mice were immunodeficient due to a lack of mature T-cells.

9. Claims 28 and 35 are drawn to compositions and methods of generating an immunodeficient non-human mammal model. The original specification provides basis for these claims at column 4, lines 9-11, and in view of the disclosure at column 2, line 66 to column 3, line 62.

20. Claims 36-38 are drawn to compositions of immunodeficient models, wherein is deleted the size limitation of 1 mm³ relating to the histologically intact human neoplastic tissue that is transplanted onto an organ of said immunodeficient models. This size limitation was included at the close of prosecution in the '735 application, without an apparent basis of rejection to which the limitation would have been addressed.

POWER OF ATTORNEY

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith

Thomas E. Ciotti (Reg No. 21,013)
Gladys H. Monroy (Reg No. 32,430)
Paul Schenck (Reg No. 27,253)
Freddie K. Park (Reg No. 35,636)
Shmuel Livnat (Reg No. 33,949)
Antoinette F. Konski (Reg No. 34,202)
Stuart P. Kaler (Reg No. 35,913)
Robert Saltzberg (Reg No. 36,910)
Mani Adeli (Reg No. 39,585)
Sean Brennan (Reg No. 39,917)
Robert K. Cerpa (Reg No. 39,933)
Lee K. Tan (Reg No. 39,447)
Madeline I. Johnston (Reg No. 36,174)
Stephen C. Durant (Reg No. 31,506)
Hector Gallegos (Reg No. 40,614)
Charles D. Holland (Reg No. 35,196)
Michael Hetherington (Reg No. 32,357)
Thomas D. Mays (Reg No. 34,524)
Wen Liu (Reg No. 32,822)
Cindy S. Kaplan (Reg No. 40,043)

Kate H. Murashige (Reg No. 29,959)
Debra A. Shetka (Reg No. 33,309)
E. Thomas Wheelock (Reg No. 28,825)
Susan K. Lehnhardt (Reg No. 33,943)
Tyler Dylan (Reg No. 37,612)
Harry J. Macey (Reg No. 32,818)
David L. Bradfute (Reg No. 39,117)
Laurie A. Axford (Reg No. 35,053)
Catherine M. Polizzi (Reg No. 40,130)
J. Michael Schiff (Reg No. 40,253)
Ronald D. Devore (Reg No. 39,958)
Alan W. Cannon (Reg No. 34,977)
Dahna S. Pasternak (Reg No. 41,411)
Frank Wu (Reg No. 41,386)
Barry E. Bretschneider (Reg No. 28,055)
Mark R. Carter (Reg No. 39,131)
Edward V. Donahue (Reg No. 35,492)
Thomas G. Wiseman (Reg No. 35,046)
Ararat Kapouytian (Reg No. 40,044)

☐ Attached as part of this declaration and power of attorney is the authorization of the above-names attorney(s) to accept and follow instructions from my representative.

all of Morrison & Foerster LLP, 2000 Pennsylvania Avenue, N.W., Washington, D.C. 20006-1888, telephone (202) 887-1500, to prosecute this application and transact all matters in the United States Patent and Trademark Office connected therewith.

Variable	Mean	SD	Min	Max
Age	34.5	10.2	22	55
Gender	Male			
Marital status	Married			
Education	High school			
Occupation	Teacher			
Income	Low			
Health status	Good			
Stress level	High			
Life satisfaction	Low			
Family size	3			
Religious belief	Religious			
Community involvement	Low			
Health insurance	Yes			
Exercise frequency	Low			
Diet quality	Low			
Sleep quality	Low			
Work-life balance	Low			
Financial stability	Low			
Emotional well-being	Low			
Physical well-being	Low			
Social well-being	Low			
Environmental well-being	Low			
Overall well-being	Low			

Issued thereon.

02/15/98

Date

AK

Name: Ann Monosov
Residence: Encinitas, CA
Citizenship: USA
Post Office Address:
1715 Edgefield Lane
Encinitas, CA 92024-1977

dc-105607